Cannabinoid Receptor

Nimacimab (RYI-018) is a negative allosteric modulating monoclonal antibody that targets the CB1 receptor. Nimacimab can be used in research on metabolic diseases.

Vicasinabin (RG7774) is an effective agonist of the cannabinoid receptor 2 (CB2). Vicasinabin has potential for researching human diseases, including chronic pain, atherosclerosis, bone regulation, neuroinflammation and other related conditions (information extracted from patent US20130116236A1).

GW 833972A is a selective CB2 receptor agonist.

MRL-650 (CB1 inverse agonist 1) is a highly potent, orally active, and specific inverse agonist of CB1 receptor with IC50s of 7.5 nM and 4100 nM for CB1 and CB2 receptors, respectively.

CB2 modulator 1 (compound 130) is a potent CB2 modulator.

PGN36 (Compound 18) is a selective cannabinoid CB2 receptor (CB2R) antagonist with a Ki of 0.09 µM.

CB1/2 agonist 1 is a potent and cross the blood-brain barrier CB1/2 agonist with EC50s of 56.15, 11.63 nM for CB1R and CB2R, respectively.

CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a CB1/CB2 (cannabinoid receptor) competitive agonist.

CB2R antagonist 3 is a selective antagonist of cannabinoid type 2 receptor (CB2R).

Monlunabant ((S)-MRI-1891) is a solid dispersions compound, as well as a cannabinoid CB1 receptor inhibitor.

GW-405833 (L768242) drochloride is a potent, selective cannabinoid receptor 2 (CB2) agonist with an EC50 of 50.7 nM.

PSB-KK1415 is a selective agonist for human orphan G protein-coupled receptor GPR18, with EC50 of 19.1 nM.

Pregnenolone -d 6 (3β-Hydroxy-5-pregnen-20-one-d 6 ) is the deuterium labeled Pregnenolone [1] . Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones.

Anandamide - 15 N (AEA- 15 N) is the 15 N-labeled Anandamide.